Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 63 articles:
HTML format
Text format



Single Articles


    December 2018
  1. SHA C, Barrans S, Cucco F, Bentley MA, et al
    Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
    J Clin Oncol. 2018 Dec 3:JCO1801314. doi: 10.1200/JCO.18.01314.
    PubMed     Text format     Abstract available


  2. CHAN WC
    Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801910. doi: 10.1200/JCO.18.01910.
    PubMed     Text format    


  3. ENNISHI D, Jiang A, Boyle M, Collinge B, et al
    Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Dec 3:JCO1801583. doi: 10.1200/JCO.18.01583.
    PubMed     Text format     Abstract available


    November 2018
  4. SARKOZY C, Maurer MJ, Link BK, Ghesquieres H, et al
    Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    J Clin Oncol. 2018 Nov 27:JCO1800400. doi: 10.1200/JCO.18.00400.
    PubMed     Text format     Abstract available


  5. SORIGUE M, Sancho JM
    Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography.
    J Clin Oncol. 2018 Nov 26:JCO1800854. doi: 10.1200/JCO.18.00854.
    PubMed     Text format    


    October 2018
  6. DAVIDS MS, von Keudell G, Portell CA, Cohen JB, et al
    Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359.
    PubMed     Text format    


  7. ALDERUCCIO JP, Zhao W, Desai A, Gallastegui N, et al
    Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution.
    J Clin Oncol. 2018 Oct 12:JCO1800138. doi: 10.1200/JCO.18.00138.
    PubMed     Text format     Abstract available


  8. LOCKMER S, Ostenstad B, Hagberg H, Holte H, et al
    Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
    J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
    PubMed     Text format     Abstract available


  9. HUNTINGTON SF, von Keudell G, Davidoff AJ, Gross CP, et al
    Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
    J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122.
    PubMed     Text format     Abstract available


    September 2018
  10. GISSELBRECHT C
    Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?
    J Clin Oncol. 2018 Sep 17:JCO1800498. doi: 10.1200/JCO.18.00498.
    PubMed     Text format    


  11. ADAMS HJA, Kwee TC
    Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 17:JCO1800323. doi: 10.1200/JCO.18.00323.
    PubMed     Text format    


  12. EVENS AM, Advani RH, Helenowski IB, Fanale M, et al
    Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    J Clin Oncol. 2018 Sep 4:JCO2018790139. doi: 10.1200/JCO.2018.79.0139.
    PubMed     Text format     Abstract available


    August 2018
  13. YANG JC, Yahalom J
    Early-Stage Follicular Lymphoma: What Is the Preferred Treatment Strategy?
    J Clin Oncol. 2018 Aug 28:JCO2018793075. doi: 10.1200/JCO.2018.79.3075.
    PubMed     Text format    


  14. KURTZ DM, Scherer F, Jin MC, Soo J, et al
    Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2018 Aug 20:JCO2018785246. doi: 10.1200/JCO.2018.78.5246.
    PubMed     Text format     Abstract available


    July 2018
  15. WEIBULL CE, Johansson ALV, Eloranta S, Smedby KE, et al
    Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators.
    J Clin Oncol. 2018 Jul 25:JCO2018783514. doi: 10.1200/JCO.2018.78.3514.
    PubMed     Text format     Abstract available


  16. SASSE S, Goergen H, Plutschow A, Boll B, et al
    Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
    J Clin Oncol. 2018 Jul 10:JCO2018787192. doi: 10.1200/JCO.2018.78.7192.
    PubMed     Text format     Abstract available


  17. SHI Q, Schmitz N, Ou FS, Dixon JG, et al
    Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    J Clin Oncol. 2018 Jul 5:JCO2018779124. doi: 10.1200/JCO.2018.77.9124.
    PubMed     Text format     Abstract available


  18. MACMANUS M, Fisher R, Roos D, O'Brien P, et al
    Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03.
    J Clin Oncol. 2018 Jul 5:JCO2018779892. doi: 10.1200/JCO.2018.77.9892.
    PubMed     Text format     Abstract available


    June 2018
  19. FRIEDBERG JW
    Progress in Advanced-Stage Follicular Lymphoma.
    J Clin Oncol. 2018 Jun 1:JCO2018793083. doi: 10.1200/JCO.2018.79.3083.
    PubMed     Text format    


  20. HIDDEMANN W, Barbui AM, Canales MA, Cannell PK, et al
    Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    J Clin Oncol. 2018 Jun 1:JCO2017768960. doi: 10.1200/JCO.2017.76.8960.
    PubMed     Text format     Abstract available


    May 2018
  21. GOPAL AK, Schuster SJ, Fowler NH, Trotman J, et al
    Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
    J Clin Oncol. 2018 May 31:JCO2017768853. doi: 10.1200/JCO.2017.76.8853.
    PubMed     Text format     Abstract available


  22. MESGUICH C, Bouabdallah K, Milpied N, Hindie E, et al
    Additional Evidence That End-of-Treatment Fluorodeoxyglucose-Positron Emission Tomography Evaluation Is Necessary in Advanced Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018786780. doi: 10.1200/JCO.2018.78.6780.
    PubMed     Text format    


  23. ADAMS HJA, Kwee TC
    Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2018 May 23:JCO2018782524. doi: 10.1200/JCO.2018.78.2524.
    PubMed     Text format    


  24. MERRYMAN RW, LaCasce AS
    Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care.
    J Clin Oncol. 2018 May 22:JCO2018789362. doi: 10.1200/JCO.2018.78.9362.
    PubMed     Text format    


  25. LETAI A
    Targeting B-Cell Lymphoma 2: A Lethal Shortcut in Del(17p) Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2018 May 22:JCO2018782763. doi: 10.1200/JCO.2018.78.2763.
    PubMed     Text format    


  26. CAMIDGE DR, Kim DW, Tiseo M, Langer CJ, et al
    Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841.
    PubMed     Text format     Abstract available


    April 2018
  27. MAURER MJ, Ghesquieres H, Link BK, Jais JP, et al
    Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
    J Clin Oncol. 2018 Apr 19:JCO2017765198. doi: 10.1200/JCO.2017.76.5198.
    PubMed     Text format     Abstract available


    March 2018
  28. CHESON BD, Chua N, Mayer J, Dueck G, et al
    Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    J Clin Oncol. 2018 Mar 27:JCO2017763656. doi: 10.1200/JCO.2017.76.3656.
    PubMed     Text format     Abstract available


  29. ARMAND P, Engert A, Younes A, Fanale M, et al
    Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    J Clin Oncol. 2018 Mar 27:JCO2017760793. doi: 10.1200/JCO.2017.76.0793.
    PubMed     Text format     Abstract available


    February 2018
  30. ROEMER MGM, Redd RA, Cader FZ, Pak CJ, et al
    Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    J Clin Oncol. 2018 Feb 2:JCO2017773994. doi: 10.1200/JCO.2017.77.3994.
    PubMed     Text format     Abstract available


    January 2018
  31. GALLAMINI A, Tarella C, Viviani S, Rossi A, et al
    Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607
    J Clin Oncol. 2018 Jan 23:JCO2017752543. doi: 10.1200/JCO.2017.75.2543.
    PubMed     Text format     Abstract available


  32. SHADMAN M, Li H, Rimsza L, Leonard JP, et al
    Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
    J Clin Oncol. 2018 Jan 22:JCO2017745083. doi: 10.1200/JCO.2017.74.5083.
    PubMed     Text format     Abstract available


  33. BOLLARD CM, Tripic T, Cruz CR, Dotti G, et al
    Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
    J Clin Oncol. 2018 Jan 9:JCO2017743179. doi: 10.1200/JCO.2017.74.3179.
    PubMed     Text format     Abstract available


    November 2017
  34. LUMINARI S, Ferrari A, Manni M, Dondi A, et al
    Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
    J Clin Oncol. 2017 Nov 2:JCO2017741652. doi: 10.1200/JCO.2017.74.1652.
    PubMed     Text format     Abstract available


    October 2017
  35. MAURER MJ, Ellin F, Srour L, Jerkeman M, et al
    International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2017 Oct 26:JCO2017738195. doi: 10.1200/JCO.2017.73.8195.
    PubMed     Text format     Abstract available


  36. DREYLING M, Santoro A, Mollica L, Leppa S, et al
    Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
    J Clin Oncol. 2017 Oct 4:JCO2017754648. doi: 10.1200/JCO.2017.75.4648.
    PubMed     Text format     Abstract available


    September 2017
  37. HERRERA AF, Armand P
    Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
    J Clin Oncol. 2017 Sep 21:JCO2017745281. doi: 10.1200/JCO.2017.74.5281.
    PubMed     Text format     Abstract available


  38. SALZ T, Zabor EC, de Nully Brown P, Dalton SO, et al
    Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2017 Sep 18:JCO2017724211. doi: 10.1200/JCO.2017.72.4211.
    PubMed     Text format     Abstract available


  39. CHAN FC, Mottok A, Gerrie AS, Power M, et al
    Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma.
    J Clin Oncol. 2017 Sep 12:JCO2017727925. doi: 10.1200/JCO.2017.72.7925.
    PubMed     Text format     Abstract available


  40. LEONARD JP, Kolibaba KS, Reeves JA, Tulpule A, et al
    Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Sep 1:JCO2017732784. doi: 10.1200/JCO.2017.73.2784.
    PubMed     Text format     Abstract available


    August 2017
  41. MARTINEZ C, Gayoso J, Canals C, Finel H, et al
    Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and
    J Clin Oncol. 2017 Aug 28:JCO2017726869. doi: 10.1200/JCO.2017.72.6869.
    PubMed     Text format     Abstract available


  42. VITOLO U, Trneny M, Belada D, Burke JM, et al
    Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2017 Aug 10:JCO2017733402. doi: 10.1200/JCO.2017.73.3402.
    PubMed     Text format     Abstract available


  43. MOSSE YP, Voss SD, Lim MS, Rolland D, et al
    Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    J Clin Oncol. 2017 Aug 8:JCO2017734830. doi: 10.1200/JCO.2017.73.4830.
    PubMed     Text format     Abstract available


    July 2017
  44. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    PubMed     Text format     Abstract available


  45. VARGO JA, Ling DC, Beriwal S
    Treatment of Early-Stage Hodgkin Lymphoma: Are We Just Shifting Morbidities?
    J Clin Oncol. 2017 Jul 6:JCO2017733568. doi: 10.1200/JCO.2017.73.3568.
    PubMed     Text format    


  46. HINDIE E, Mesguich C, Zanotti-Fregonara P
    On the Role of Interim Fluorine-18-Labeled Fluorodeoxyglucose Positron Emission Tomography in Early-Stage Favorable Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017738369. doi: 10.1200/JCO.2017.73.8369.
    PubMed     Text format    


  47. ADAMS HJA, Kwee TC
    Interim Fluorodeoxyglucose Positron Emission Tomography-Adapted Therapy Is Not an Efficient Approach to Improving Outcome in Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2017 Jul 6:JCO2017733816. doi: 10.1200/JCO.2017.73.3816.
    PubMed     Text format    


    June 2017
  48. LEONARD JP, Martin P, Roboz GJ
    Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
    J Clin Oncol. 2017 Jun 27:JCO2017726745. doi: 10.1200/JCO.2017.72.6745.
    PubMed     Text format     Abstract available


  49. GROMMES C, DeAngelis LM
    Primary CNS Lymphoma.
    J Clin Oncol. 2017 Jun 22:JCO2017727602. doi: 10.1200/JCO.2017.72.7602.
    PubMed     Text format     Abstract available


    May 2017
  50. STAIGER AM, Ziepert M, Horn H, Scott DW, et al
    Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    J Clin Oncol. 2017 May 19:JCO2016703660. doi: 10.1200/JCO.2016.70.3660.
    PubMed     Text format     Abstract available


  51. WITZIG TE
    Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits?
    J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578.
    PubMed     Text format    


  52. OU SI
    Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2017 May 11:JCO2017731323. doi: 10.1200/JCO.2017.73.1323.
    PubMed     Text format    


  53. LANDSBURG DJ, Falkiewicz MK, Maly J, Blum KA, et al
    Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    J Clin Oncol. 2017 May 5:JCO2017722157. doi: 10.1200/JCO.2017.72.2157.
    PubMed     Text format     Abstract available


  54. KIM DW, Tiseo M, Ahn MJ, Reckamp KL, et al
    Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 May 5:JCO2016715904. doi: 10.1200/JCO.2016.71.5904.
    PubMed     Text format     Abstract available


  55. LAURENT C, Baron M, Amara N, Haioun C, et al
    Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.
    J Clin Oncol. 2017 May 1:JCO2016712083. doi: 10.1200/JCO.2016.71.2083.
    PubMed     Text format     Abstract available


    April 2017
  56. KAMDAR MK, Smith SM
    Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick.
    J Clin Oncol. 2017 Apr 27:JCO2017722835. doi: 10.1200/JCO.2017.72.2835.
    PubMed     Text format     Abstract available


  57. CHEN R, Zinzani PL, Fanale MA, Armand P, et al
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
    J Clin Oncol. 2017 Apr 25:JCO2016721316. doi: 10.1200/JCO.2016.72.1316.
    PubMed     Text format     Abstract available


  58. THIEBLEMONT C, Tilly H, Gomes da Silva M, Casasnovas RO, et al
    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol. 2017 Apr 20:JCO2017726984. doi: 10.1200/JCO.2017.72.6984.
    PubMed     Text format     Abstract available


  59. SASSE S, Brockelmann PJ, Goergen H, Plutschow A, et al
    Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    J Clin Oncol. 2017 Apr 18:JCO2016709410. doi: 10.1200/JCO.2016.70.9410.
    PubMed     Text format     Abstract available


  60. MEYER RM
    Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty.
    J Clin Oncol. 2017 Apr 3:JCO2017722611. doi: 10.1200/JCO.2017.72.2611.
    PubMed     Text format    


    March 2017
  61. ZUCCA E, Conconi A, Martinelli G, Bouabdallah R, et al
    Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
    J Clin Oncol. 2017 Mar 29:JCO2016706994. doi: 10.1200/JCO.2016.70.6994.
    PubMed     Text format     Abstract available


  62. SUD A, Thomsen H, Sundquist K, Houlston RS, et al
    Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.
    J Clin Oncol. 2017 Mar 13:JCO2016709709. doi: 10.1200/JCO.2016.70.9709.
    PubMed     Text format     Abstract available


    January 2017
  63. HERRERA AF, Mei M, Low L, Kim HT, et al
    Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
    J Clin Oncol. 2017;35:24-31.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: